肿瘤微环境(TME)-响应型纳米酶介导的化学动力疗法(CDT)在口腔鳞状细胞癌中已有了广泛的研究。然而，由于TME中过氧化氢不足而导致低催化效率仍然是其临床应用的主要挑战。因此，本文提出了一种基于Mn-Co有机金属框架材料(MnCoMOF)的抗肿瘤纳米平台，展示了其类过氧化物酶(POD)活性和载荷葡萄糖氧化酶(GOx @ MnCoMOF)的能力，展示出H2O2自供和H2O2转化为有毒羟基自由基。封装的GOx可以高效地在肿瘤部位将葡萄糖催化成葡萄糖酸和H2O2，以切断能量供应以抑制肿瘤生长，并产生大量的H2O2和酸来弥补其在肿瘤微环境中的缺乏。MnCoMOF的POD-like活性可以将H2O2转化为羟基自由基并消灭肿瘤细胞。纳米平台在高葡萄糖介质中表现出增强的肿瘤细胞细胞毒性，说明葡萄糖经GOx转化为H2O2的产生充分。体内实验结果表明，GOx @ MnCoMOF具有出色的抗肿瘤功效，并可以重塑免疫抑制的肿瘤微环境。总之，GOx @ MnCoMOF纳米平台具有双重酶活性，即POD-like和葡萄糖氧化酶，通过协同饥饿和化学动力治疗实现了改善的肿瘤抑制效率，为口腔癌的临床治疗提供了新的策略。

Tumor microenvironment (TME)-responsive chemodynamic therapy (CDT) mediated by nanozymes has been extensively studied in oral squamous cell carcinoma. However, the low catalytic efficiency due to insufficient H2O2 in the TME is still a major challenge for its clinical translation. Herein, we present an antitumor nanoplatform based on a Mn-Co organometallic framework material (MnCoMOF), which shows peroxidase-like (POD-like) activity, loaded with glucose oxidase (GOx@MnCoMOF), demonstrating the ability of H2O2 self-supply and H2O2 conversion to toxic hydroxyl radicals. The encapsulated GOx efficiently catalyzes glucose into gluconic acid and H2O2 at the tumor site, which can cut off the energy supply to inhibit tumor growth and produce a large amount of H2O2 and acid to compensate for their lack in the tumor microenvironment. The POD-like activity of MnCoMOF can convert H2O2 into hydroxyl radicals and eliminate tumor cells. The nanoplatform exhibits enhanced tumor cell cytotoxicity in a high-glucose medium compared with a low-glucose medium, illustrating sufficient generation of H2O2 from glucose by GOx. The in vivo results indicate that GOx@MnCoMOF has excellent antitumor efficacy and can remodel the immune-suppressive tumor microenvironment. In conclusion, the GOx@MnCoMOF nanoplatform possesses dual enzymatic activities, i.e., POD-like and glucose oxidase, to achieve improved tumor-suppressive efficiency through synergistic starvation and chemodynamic therapy, thus providing a new strategy for the clinical treatment of oral cancer.